Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Abacor - Nutraceuticals World

What are you searching for?

Sign in
Research

Abacor

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Indication: Cholesterol levels in statin-treated patients

Source: New Functional Ingredients & Foods meeting held in April in Copenhagen, Denmark.

Research: The purpose of the study was to test whether Abacor, a newly developed dietary supplement containing isolated soy protein, phospholipids and fibers has an additional cholesterol lowering effect in patients treated with a lipid lowering drug from the group of 3-hydoxy-3-methylglutaryl coenzyme reductase inhibitors (statins) but having plasma concentrations above target values. Eligible for the study were patients treated with statins having a plasma low density lipoprotein (LDL) cholesterol concentration above 3 mmol/L. In total, 67 subjects were screened, 53 (79%) were eligible for participation and 49 subjects (15 women/34 men, 43-79 years) completed the study. All patients received their usual statin dose for six weeks followed by six weeks of statin + Abacor and finally six weeks of usual statin does.

Results: Plasma total cholesterol and LDL cholesterol concentrations were significantly lower after six weeks of combination treatment 5.5 mmol/L and 3.3 mmol/L, respectively, than the mean value of the concentrations after the two periods of six weeks statin monotherapy, 5.0 mmol/L and 3.6 mmol/L, respectively. No significant differences in plasma HDL cholesterol and triglyceride concentrations were found. Compliance to consumption of both Abacor® and statin was high, 95% and 98%, respectively. No significant differences in the number of adverse events were found between the combination period and the statin monotherapy periods.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters